Inhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy

Area of Science:

• Molecular Biology
• Genetics
• Biochemistry

Background:

• Duchenne muscular dystrophy (DMD) is a severe X-linked genetic disorder.
• Glucocorticoids are the primary therapy for DMD, but their mechanism is unclear and additional treatments are needed.

Purpose of the Study:

• Investigate pathogenic mechanisms in DMD.
• Clarify the molecular effects of glucocorticoids.
• Identify novel therapeutic targets for DMD.

Main Methods:

• Single-nucleus RNA sequencing of human and mouse muscle tissue.
• Spatial transcriptome analysis.
• Administration of EZH2 inhibitors to Dmd mutant mice.

Main Results:

• Identified increased activity of the EZH2 signaling pathway in DMD patient cells.
• EZH2 inhibition in mice improved muscle phenotype.
• EZH2 inhibitors maintained immune suppression while counteracting glucocorticoid-induced muscle weakness and fibrosis.

Conclusions:

• The EZH2 pathway is a key pathogenic mechanism in DMD.
• Targeting EZH2 offers a promising strategy to enhance current DMD therapies.
• EZH2 inhibitors represent a potential complementary treatment for Duchenne muscular dystrophy.